Tag: ATH434

Phase-II of the ATH434 trial for multiple system atrophy patient dosing has started, according to Alterity Therapeutics.

The first participant in Alterity Therapeutics’ phase 2 clinical trial of ATH434 in multiple system atrophy (MSA), a rare and severely handicapping Parkinson’s disease, has been dosed in the US, according to the biotechnology company’s announcement. Alterity Therapeutics is dedicated…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram